Molecules containing more than 50 amino acids are called proteins. Proteins are generally produced as active ingredients in biotechnological drugs using biological methods, typically from living organisms or cellular systems. However, some proteins can also be produced using synthetic or semi-synthetic methods.

Examples of protein-containing drugs include certain blood products, hormones, and immunological products. Due to their complex structures and production processes, these products require specialized manufacturing, purification, and quality control approaches. Biosimilar drugs, on the other hand, are biological drugs developed after the expiration of the patent period of the original biotechnological product; their similarity to the reference product in terms of quality, safety, and efficacy has been demonstrated through extensive studies.

Proteins are used not only in the pharmaceutical field but also in dietary supplements. Protein supplements are generally formulated to support nutrition, for sports nutrition, the elderly, or groups with special nutritional needs. The proteins in these products are not intended for therapeutic purposes but are evaluated based on their nutritional value. CT Pharma Research provides consulting services for the development of biosimilar drugs in accordance with current regulations. It also specializes in the development of protein supplements